These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25845252)

  • 1. Estimation of angiotensin-converting enzyme inhibitors protein binding degree using chromatographic hydrophobicity data.
    Trbojević-Stanković J; Aleksić M; Odović J
    Srp Arh Celok Lek; 2015; 143(1-2):50-5. PubMed ID: 25845252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between ultra-high performance liquid chromatography-tandem mass spectrometry and reversed-phase thin-layer chromatography hydrophobicity data for evaluation of angiotensin-converting enzyme inhibitors absorption.
    Odovic JV; Markovic BD; Injac RD; Vladimirov SM; Karljikovic-Rajic KD
    J Chromatogr A; 2012 Oct; 1258():94-100. PubMed ID: 22939460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro modeling of angiotensin-converting enzyme inhibitor's absorption with chromatographic retention data and selected molecular descriptors.
    Odović J; Marković B; Vladimirov S; Karljiković-Rajić K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Mar; 953-954():102-7. PubMed ID: 24583202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipophilicity Examination of Some ACE inhibitors andHydrochlorothiazide on Cellulose in RP Thin-Layer Chromatography.
    Odović J; Karljiković-Rajić K; Trbojević-Stanković J; Stojimirović B; Vladimirov S
    Iran J Pharm Res; 2012; 11(3):763-70. PubMed ID: 24250503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of angiotensin-converting enzyme inhibitor's absorption with retention data of micellar thin-layer chromatography and suitable molecular descriptor.
    Odovic J; Markovic B; Vladimirov S; Karljikovic-Rajic K
    J Chromatogr Sci; 2015; 53(10):1780-5. PubMed ID: 26123666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the angiotensin-converting-enzyme inhibitors.
    Piepho RW
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S3-7. PubMed ID: 11030016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: interaction of ACE inhibitors with high-affinity H+/peptide symporter.
    Lin CJ; Akarawut W; Smith DE
    Pharm Res; 1999 May; 16(5):609-15. PubMed ID: 10350000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors.
    Ranadive SA; Chen AX; Serajuddin AT
    Pharm Res; 1992 Nov; 9(11):1480-6. PubMed ID: 1475237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE".
    Ruzicka M; Coletta E; White R; Davies R; Haddad H; Leenen FH
    Am J Hypertens; 2010 Nov; 23(11):1179-82. PubMed ID: 20634797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-converting enzyme inhibitors: recent therapeutic aspect].
    Shionoiri H; Shigemasa T; Takasaki I
    Nihon Rinsho; 1997 Aug; 55(8):2067-74. PubMed ID: 9284425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.
    Woie L; Dickstein K; Kaada B
    Gen Pharmacol; 1987; 18(6):577-87. PubMed ID: 2822521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans.
    Derad I; Otterbein A; Mölle M; Pietrowsky R; Born J; Fehm HL
    J Hypertens; 1996 Nov; 14(11):1309-15. PubMed ID: 8934359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
    MacFadyen RJ; Lee AF; Morton JJ; Pringle SD; Struthers AD
    Heart; 1999 Jul; 82(1):57-61. PubMed ID: 10377310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme inhibitors on the power spectrum of heart rate variability in post-myocardial infarction patients.
    Kontopoulos AG; Athyros VG; Papageorgiou AA; Skeberis VM; Basayiannis EC; Boudoulas H
    Coron Artery Dis; 1997; 8(8-9):517-24. PubMed ID: 9431480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
    Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.